The immune reconstitution remains the most desirable goal for treatment of PML and all treatment strategies aimed at the restoration of cellular immunity, particularly JCV-specific CD8 and CD4 T cells [17]. This evidence concerns the gene CD8A and progressive multifocal leukoencephalopathy.